FDA Approves First Biosimilars Interchangeable With Simponi/Simponi Aria

Bone Health in Oncology: Closing Gaps, Reducing Costs, and Unlocking Biosimilar Value

March 30th 2026

Biosimilar CT-P43 Matches Ustekinumab in Treating Moderate to Severe Plaque Psoriasis

March 20th 2026

By AJMC Staff

A phase 3 clinical trial found that the ustekinumab biosimilar CT-P43 demonstrated equivalent efficacy, safety, and immunogenicity to reference ustekinumab in patients with moderate to severe plaque psoriasis.

Golimumab Biosimilar Matches Reference Drug in Year-Long RA Trial

March 19th 2026

By Skylar Jeremias

One-year trial shows AVT05 golimumab biosimilar matches Simponi in rheumatoid arthritis, including switching, with comparable safety and immunogenicity outcomes.

Switching to Biosimilar Etanercept Shows No Impact on Efficacy, Safety Across 18 Trials

March 16th 2026

By Skylar Jeremias

Real-world evidence shows switching between etanercept products and etanercept biosimilars preserves efficacy and safety, easing concerns and highlighting nocebo challenges.

Gaps in Knowledge Persist Around Biosimilar Insulin Switching, Review Finds

March 12th 2026

By Skylar Jeremias

Scoping review shows clinicians and patients still worry about biosimilar insulin switching, devices and safety—evidence gaps shape insulin product swaps.

Global Biosimilar Market Sees Structural Shifts, Regulatory Hurdles, and Pipeline Gains

March 10th 2026

By Skylar Jeremias

Global biosimilar market shifts: Celltrion leads biosimilars in Asia, biosimilars in Europe expand, while Sandoz restructures and FDA hurdles loom.

FDA Issues Draft Guidance Aimed at Cutting Expenses for Biosimilar PK Studies

March 9th 2026

By Skylar Jeremias

Biologics eat 51% of drug spending despite being 5% of prescriptions, but the FDA's new draft guidance hopes more competition can close that gap.

Clinician Confidence in Ophthalmology Biosimilars Remains Low Across Europe

March 6th 2026

By Skylar Jeremias

A new analysis dives into why Europe’s eye clinics lag on biosimilars and how education, guidance, and smarter tenders could unlock €747 million in savings.

Biosimilars Development Roundup: Expanding Global Options Amidst Rising US Legal Hurdles

March 5th 2026

By Skylar Jeremias

CHMP backs a fifth teriparatide biosimilar as biosimilars in Europe grow, while US patent fights threaten new biologic competition.

Biosimilar-Backed Triplet Regimen Shows Feasibility in Heavily Pretreated Liver Cancer

February 27th 2026

By Skylar Jeremias

A phase 2 trial showed that combining targeted radiotherapy with PD-1 blockade and a bevacizumab biosimilar can elicit responses in advanced liver cancer.